FluoGuide A/S (FRA:96X)

Market Cap	56.34M -1.3%
Revenue (ttm)	-63.60K -9.0%
Net Income	-4.70M
EPS	-0.34
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	3
Open	3.100
Previous Close	3.130
Day's Range	3.100 - 3.100
52-Week Range	2.620 - 4.035
Beta	n/a
RSI	51.53
Earnings Date	Feb 25, 2026

About FluoGuide

FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company has a collaboration agreement with ZEISS Medical Technologies for the development of FG001 for tumor imaging and surgical margins assessment for head and neck cancer. FluoGuide A/S was incorporated in ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2018
• Employees: 8
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 96X

Financial Performance

In 2024, FluoGuide's revenue was 385,000, a decrease of -8.98% compared to the previous year's 423,000. Losses were -28.96 million, -24.54% less than in 2023.

Financial numbers in DKK